The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Evaluation of Radiation Therapy Positioning System (RTPS) in Patients With Localized Prostate Cancer
Official Title: Evaluation of Radiation Therapy Positioning System (RTPS) in Patients With Localized Prostate Cancer
Study ID: NCT00921193
Brief Summary: The study aims to evaluate the safety and performance of the RTPS in patients with localized prostate cancer.The RTPS is an investigational device and requires permanent implantation of a small radioactive fiducial, called the Blip, in the prostate.
Detailed Description: The high precision of planned radiotherapy treatments requires accurate positioning of the prostate in order to ensure that the tightly conformed dose distribution does not miss the prostate and result in either significant tumor underdosage, an increased dose to the rectum or bladder, or both. Precise delivery has been addressed using a variety of pre-treatment localization systems. The most direct localization of the prostate involves the use of ultrasound, computed tomography (CT), or radiography of permanently implanted fiducial markers. In this study the safety and performance of a novel investigational tracking system will be evaluated. The Radiation Therapy Positioning System (RTPS) is a radioactive tracking system integrated into the radiotherapy set-up workflow. The System is composed of the Clinical Positioning System (CPS) and a radioactive soft tissue implanted fiducial (Blip), which is permanently implanted in the prostate. By tracking the implanted Blip, the CPS can monitor positional changes prior to and during the treatment. The accuracy of the RTPS localization will be compared to the CBCT in at least 5 radiation therapy sessions per patient.
Minimum Age: 45 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Leuvens Kankerinstituut, Leuven, , Belgium
Dr. Bernard Verbeeten Institute, Tilburg, , Netherlands
Name: Philip MP Poortmans, MD, PhD
Affiliation: Dr. Bernard Verbeeten Instituut
Role: PRINCIPAL_INVESTIGATOR
Name: Willy JM de Kruijf, PhD
Affiliation: Dr. Bernard Verbeeten Instituut
Role: PRINCIPAL_INVESTIGATOR
Name: Karin Haustermans, MD
Affiliation: Leuvens Kankerinstituut
Role: PRINCIPAL_INVESTIGATOR